CTOs on the Move

ViroCyt

www.virocyt.com

 
ViroCyt is the leader in the field of rapid virus quantification. Our goal is to provide the tools that deliver meaningful improvements to mission critical processes, such as vaccine manufacturing, protein expression, antiviral development and other settings where viruses play a significant role.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.virocyt.com
  • 2100 Central Avenue Suite 103
    Boulder, CO USA 80301
  • Phone: 720.599.3700

Executives

Name Title Contact Details
Michael Olszowy
Chief Technology Officer Profile

Similar Companies

Neuralink

Neuralink is developing the capabilities of the brain through technological augmentation. A "neural lace” would be surgically connected to a human brain and allow a user to interact with a computer without the bandwidth challenges that come with current input methods, including keyboards, mice and trackpads. Neuralink will explore how brain interfaces might alleviate the symptoms of dangerous and chronic medical conditions.

Novartis Consumer Health Inc

Novartis Consumer Health Inc is a Big Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Logical Therapeutics

Logical Therapeutics is a Foxboro, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CM-Tec Inc

CM-Tec Inc is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Turnstone Biologics

Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone`s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing treatment times to patients. The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01, and is expecting to file an IND for the lead TIL therapy candidate, TIDAL-01, in 2021.